HOXA10 and acute myeloid leukemia: Finally, we provided a proof of principle of how HOXA10-AS could be leveraged towards clinical implementation, by demonstrating HOXA10-AS as a prognostic marker in AML and potential therapeutic target in pediatric KMT2A-r AML [70].